Chongqing Huapont Pharmaceutical, a wholly-owned subsidiary of Huapont Health, has obtained the Drug Registration Certificate for Ibrutinib Tablets approved and issued by the National Medical Products Administration. The drug specifications are 0.14 grams and 420 milligrams, with a registration classification of chemical drug category 3, deemed to have passed the generic drug quality and efficacy consistency evaluation. Ibrutinib Tablets are indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and Waldenström macroglobulinemia. The company stated that this approval will enrich its anti-tumor product pipeline, and it will initiate production and sales as soon as possible after the patent expires, though market competition remains uncertain.
Huapont Life Sciences Co LtdSubsidiary receives drug registration certificate for Ibrutinib Tablets, enriching anti-tumor pipeline.
Wholly-owned subsidiary obtains drug registration certificate for Ibrutinib Tablets.